Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aclaris Therapeutics

1.56
+0.03001.96%
Post-market: 1.53-0.0300-1.92%19:15 EDT
Volume:666.22K
Turnover:1.02M
Market Cap:168.92M
PE:-1.08
High:1.56
Open:1.53
Low:1.50
Close:1.53
Loading ...

Aclaris Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
01 Aug

Aclaris announces ATI-2138 trial meets primary, secondary endpoints

TIPRANKS
·
30 Jul

Aclaris Therapeutics Inc - Primary Endpoint Confirms Favorable Tolerability Profile of ATI-2138

THOMSON REUTERS
·
30 Jul

Aclaris Therapeutics Inc - ATI-2138 Well Tolerated With No Severe Adverse Events

THOMSON REUTERS
·
30 Jul

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

GlobeNewswire
·
30 Jul

Aclaris Therapeutics Announces Leadership Transition

GlobeNewswire
·
28 Jul

Aclaris Therapeutics Coverage Assumed by Piper Sandler at Overweight

Dow Jones
·
10 Jul

Aclaris Therapeutics assumed with an Overweight at Piper Sandler

TIPRANKS
·
10 Jul

Aclaris Therapeutics Highlights Clinical Pipeline and Outlook

TIPRANKS
·
30 Jun

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Jun

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

TIPRANKS
·
25 Jun

BRIEF-Aclaris Therapeutics Initiates Phase 1A/1B Program For Its Novel Bispecific Antibody Ati-052

Reuters
·
23 Jun

Wedbush Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)

TIPRANKS
·
09 Jun

Aclaris Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
06 Jun

BRIEF-Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis

Reuters
·
02 Jun

Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments

TIPRANKS
·
30 May

Aclaris Therapeutics Initiated at Outperform by Wedbush

Dow Jones
·
28 May

Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target

MT Newswires Live
·
28 May

Aclaris Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
15 May

Aclaris Therapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
10 May